Metzgeroth G, Hastka J
III. Medizinische Klinik, Hämatologie und Internistische Onkologie, Universitätsmedizin Mannheim, Medizinische Fakultät Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland,
Internist (Berl). 2015 Sep;56(9):978-88. doi: 10.1007/s00108-015-3711-2.
Hypochromic-microcytic anemias are characterized by a hemoglobin deficiency of the erythrocytes. The main reason for the insufficient hemoglobin synthesis is, with exception of thalassemia and a few other rare conditions, primarily a disorder of iron metabolism. Differential diagnostic considerations are focused on iron deficiency anemia, with approximately 80% the most common form of anemia worldwide. Iron deficiency anemia shows a particularly high prevalence in developing countries, but is also in industrialized Western countries the most common cause of anemia. Infants, toddlers, premenopausal or pregnant women, and elderly people are at particularly high risk of iron deficiency anemia. The most important differential diagnosis for iron deficiency anemia is the anemia of chronic disorders (ACD). This anemia is caused by a disturbance of iron utilization (functional iron deficiency), in which iron absorption and iron release, as a nonspecific defense mechanism, is blocked to restrict iron availability for the inflammatory process but also withhold iron from the erythropoiesis. ACD is not rare, but plays a significant role in hospitalized patients and in the elderly. The differentiation between ACD and iron deficiency anemia is highly important from a clinical point of view, due to different types of further management. The cause for iron deficiency should be clarified in each case, whereas the etiology for ACD is often obvious. The standard treatment of iron deficiency anemia is oral iron supplementation. Intravenous iron application is reserved for problem patients. The best treatment for ACD is the elimination of the underlying chronic disorder. In case of persistent ACD, red blood cell transfusions, erythropoietin, and intravenous iron are used therapeutically.
低色素小细胞性贫血的特征是红细胞血红蛋白缺乏。除地中海贫血和其他少数罕见情况外,血红蛋白合成不足的主要原因主要是铁代谢紊乱。鉴别诊断主要考虑缺铁性贫血,它是全球约80%最常见的贫血形式。缺铁性贫血在发展中国家尤为普遍,但在西方工业化国家也是贫血最常见的原因。婴儿、幼儿、绝经前或孕妇以及老年人患缺铁性贫血的风险特别高。缺铁性贫血最重要的鉴别诊断是慢性病贫血(ACD)。这种贫血是由铁利用障碍(功能性缺铁)引起的,在这种情况下,作为一种非特异性防御机制,铁的吸收和释放被阻断,以限制炎症过程中铁的可用性,同时也阻止铁用于红细胞生成。ACD并不罕见,但在住院患者和老年人中起重要作用。从临床角度来看,区分ACD和缺铁性贫血非常重要,因为后续治疗方式不同。每种情况下都应明确缺铁的原因,而ACD的病因通常很明显。缺铁性贫血的标准治疗方法是口服铁补充剂。静脉注射铁剂仅用于有问题的患者。ACD的最佳治疗方法是消除潜在的慢性疾病。对于持续性ACD,可采用红细胞输血、促红细胞生成素和静脉注射铁剂进行治疗。